ATLANTA--(EON: Enhanced Online News)--InVasc Therapeutics, Inc., a leading developer of drugs for chronic kidney and cardiometabolic diseases, announced today that two thought leaders, George L. Bakris, M.D. and Gordon H. Williams, M.D., have been appointed to InVasc’s Scientific Advisory Board (SAB). These distinguished clinician-scientists will provide guidance to InVasc as it advances its portfolio of products through preclinical and clinical development.

“these experts will play an important advisory role in assuring our development programs are best positioned for clinical success.”

George L. Bakris, M.D., a nephrologist, is a Professor of Medicine in Chicago. Dr. Bakris is well known having published over 500 articles and book chapters in the areas of diabetic kidney disease, hypertension and the progression of nephropathy. He is also the editor or co-editor of eight books in the areas of kidney disease progression and diabetes. He chaired the first National Kidney Foundation Consensus report on blood pressure and its impact on renal disease progression. Dr. Bakris is the current president of the American Society of Hypertension and is on the board of the National Kidney Foundation. He is also the current Editor of the American Journal of Nephrology, the Hypertension Section Editor of Up-To-Date and an Associate Editor of Diabetes Care.

Gordon H. Williams, M.D., an endocrinologist, has been a Professor of Medicine in Boston since 1981. Dr. Williams’ research has focused on the genetics of complex diseases involving hormonal mechanisms, specifically hypertension and diabetes mellitus. He has published over 500 original articles, reviews, chapters and books. Dr. Williams is a past recipient of the Robert Tigerstedt Distinguished Scientist Award from the American Society of Hypertension, and the 2010 Clinical Research Prize of the American Heart Association.

“These additions significantly strengthen InVasc’s ability to assess its developmental programs and advance select candidates through clinical development,” said Dr. Sanjay Rajagopalan, M.D., acting chairman of InVasc’s SAB. Bill Johnston, Ph.D., CEO of InVasc, indicated, “these experts will play an important advisory role in assuring our development programs are best positioned for clinical success.”

About InVasc

InVasc Therapeutics, Inc., headquartered in Norcross, Georgia, is a biopharmaceutical company developing drugs to mitigate risks associated with chronic kidney and cardiometabolic diseases. Cardiovascular and metabolic diseases such as diabetes, hypertension, stroke and dyslipidemia are the leading causes of morbidity and mortality. The Company is currently conducting a Phase IIa clinical trial with INV-144 to delay the progression of chronic kidney disease. InVasc’s pipeline development is supported by two SBIR grants.

...